Lv6
2560 积分 2022-06-14 加入
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
12天前
已完结
Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?
14天前
已完结
The current state of the art and future trends in RAS-targeted cancer therapies
26天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1个月前
已完结
Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: the phase I/II randomized NAPAN trial
3个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
4个月前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
4个月前
已完结
An overview of KRAS G12D inhibitors: Expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities
4个月前
已完结
The role of alternative splicing in cancer drug resistance
4个月前
已完结
皖公网安备34019202002308
